| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 55 | 2024 | 894 | 6.310 |
Why?
|
| Melanoma | 28 | 2019 | 954 | 2.830 |
Why?
|
| Nevus | 10 | 2016 | 35 | 1.590 |
Why?
|
| Nevus, Pigmented | 9 | 2014 | 31 | 1.460 |
Why?
|
| Dysplastic Nevus Syndrome | 7 | 2017 | 21 | 1.430 |
Why?
|
| Histiocytoma, Benign Fibrous | 3 | 2024 | 12 | 1.380 |
Why?
|
| Mycosis Fungoides | 4 | 2016 | 15 | 1.320 |
Why?
|
| Carcinoma, Basal Cell | 3 | 2024 | 68 | 1.100 |
Why?
|
| Drug Eruptions | 2 | 2021 | 33 | 1.090 |
Why?
|
| Diagnosis, Differential | 23 | 2024 | 1973 | 1.020 |
Why?
|
| Immunohistochemistry | 24 | 2019 | 1744 | 0.860 |
Why?
|
| Chickenpox | 1 | 2024 | 22 | 0.860 |
Why?
|
| Hemorrhoids | 1 | 2024 | 11 | 0.860 |
Why?
|
| Herpes Zoster | 1 | 2024 | 26 | 0.860 |
Why?
|
| Skin | 6 | 2019 | 546 | 0.790 |
Why?
|
| Staining and Labeling | 3 | 2021 | 184 | 0.770 |
Why?
|
| Skin Diseases | 4 | 2022 | 137 | 0.770 |
Why?
|
| Paget Disease, Extramammary | 1 | 2021 | 4 | 0.720 |
Why?
|
| Colitis, Ulcerative | 1 | 2024 | 218 | 0.710 |
Why?
|
| Adenine | 1 | 2021 | 123 | 0.690 |
Why?
|
| Artifacts | 1 | 2021 | 114 | 0.660 |
Why?
|
| Piperidines | 1 | 2021 | 237 | 0.630 |
Why?
|
| Melanoma-Specific Antigens | 4 | 2014 | 9 | 0.620 |
Why?
|
| Biomarkers, Tumor | 13 | 2022 | 1688 | 0.590 |
Why?
|
| Sezary Syndrome | 2 | 2011 | 14 | 0.590 |
Why?
|
| Mucinosis, Follicular | 2 | 2021 | 2 | 0.570 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2021 | 175 | 0.570 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2017 | 5 | 0.540 |
Why?
|
| Humans | 88 | 2024 | 133015 | 0.520 |
Why?
|
| Melanocytes | 7 | 2022 | 48 | 0.500 |
Why?
|
| Dermatofibrosarcoma | 2 | 2008 | 18 | 0.490 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2008 | 64 | 0.490 |
Why?
|
| Pathology | 2 | 2015 | 36 | 0.480 |
Why?
|
| Dermatology | 1 | 2015 | 31 | 0.470 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2014 | 25 | 0.450 |
Why?
|
| Cryotherapy | 1 | 2014 | 21 | 0.450 |
Why?
|
| Steroids | 1 | 2015 | 210 | 0.440 |
Why?
|
| Truth Disclosure | 1 | 2015 | 105 | 0.440 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2014 | 64 | 0.440 |
Why?
|
| Male | 44 | 2024 | 65312 | 0.430 |
Why?
|
| Aged | 25 | 2024 | 21483 | 0.420 |
Why?
|
| Neoplasms, Second Primary | 3 | 2013 | 150 | 0.410 |
Why?
|
| Diagnostic Errors | 2 | 2015 | 349 | 0.400 |
Why?
|
| Eyelid Neoplasms | 2 | 2016 | 28 | 0.400 |
Why?
|
| Nephrogenic Fibrosing Dermopathy | 1 | 2012 | 4 | 0.400 |
Why?
|
| Margins of Excision | 3 | 2017 | 59 | 0.400 |
Why?
|
| Dermatomycoses | 1 | 2012 | 18 | 0.390 |
Why?
|
| Neoplasm Proteins | 3 | 2008 | 713 | 0.390 |
Why?
|
| Immunocompromised Host | 2 | 2013 | 307 | 0.390 |
Why?
|
| Leuprolide | 1 | 2012 | 23 | 0.390 |
Why?
|
| Ethics, Medical | 1 | 2015 | 401 | 0.380 |
Why?
|
| Sweat Gland Neoplasms | 3 | 2013 | 16 | 0.380 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2016 | 1311 | 0.360 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2012 | 270 | 0.340 |
Why?
|
| Antigens, CD | 3 | 2008 | 440 | 0.340 |
Why?
|
| Sentinel Lymph Node Biopsy | 3 | 2009 | 72 | 0.330 |
Why?
|
| Acanthoma | 2 | 2022 | 5 | 0.330 |
Why?
|
| Adult | 25 | 2024 | 31723 | 0.310 |
Why?
|
| Receptors, Leptin | 2 | 2010 | 42 | 0.310 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2011 | 225 | 0.310 |
Why?
|
| Cell Adhesion Molecules | 2 | 2008 | 239 | 0.310 |
Why?
|
| Cryosurgery | 1 | 2009 | 47 | 0.300 |
Why?
|
| Nose Neoplasms | 1 | 2008 | 35 | 0.290 |
Why?
|
| Nevus, Blue | 1 | 2008 | 2 | 0.290 |
Why?
|
| Giant Cell Tumors | 1 | 2008 | 5 | 0.290 |
Why?
|
| Arm | 1 | 2008 | 81 | 0.280 |
Why?
|
| Aged, 80 and over | 16 | 2019 | 7165 | 0.280 |
Why?
|
| Nitrogen | 3 | 2014 | 147 | 0.270 |
Why?
|
| Middle Aged | 30 | 2024 | 29016 | 0.270 |
Why?
|
| Receptors, Thyrotropin | 1 | 2006 | 12 | 0.260 |
Why?
|
| Scalp | 2 | 2024 | 58 | 0.260 |
Why?
|
| Thyrotropin | 1 | 2006 | 61 | 0.260 |
Why?
|
| Granuloma, Pyogenic | 1 | 2016 | 6 | 0.250 |
Why?
|
| Female | 35 | 2024 | 71346 | 0.250 |
Why?
|
| Conjunctival Neoplasms | 1 | 2006 | 15 | 0.250 |
Why?
|
| Neoplasm Invasiveness | 1 | 2008 | 674 | 0.240 |
Why?
|
| Actins | 1 | 2008 | 340 | 0.240 |
Why?
|
| Specimen Handling | 1 | 2006 | 149 | 0.230 |
Why?
|
| Lymphocyte Subsets | 1 | 2005 | 41 | 0.230 |
Why?
|
| Carcinosarcoma | 2 | 2015 | 12 | 0.230 |
Why?
|
| Hamartoma Syndrome, Multiple | 2 | 2016 | 20 | 0.220 |
Why?
|
| Sarcoma, Kaposi | 1 | 2016 | 131 | 0.220 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2006 | 259 | 0.220 |
Why?
|
| Fibrosis | 2 | 2019 | 426 | 0.220 |
Why?
|
| Hemangiosarcoma | 2 | 2016 | 46 | 0.220 |
Why?
|
| MART-1 Antigen | 3 | 2022 | 14 | 0.220 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2005 | 144 | 0.220 |
Why?
|
| Herpesvirus 3, Human | 1 | 2024 | 30 | 0.210 |
Why?
|
| Giant Cells | 1 | 2004 | 36 | 0.210 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2003 | 15 | 0.210 |
Why?
|
| Heel | 1 | 2023 | 9 | 0.210 |
Why?
|
| Fibroma | 1 | 2004 | 31 | 0.210 |
Why?
|
| gp100 Melanoma Antigen | 2 | 2014 | 5 | 0.210 |
Why?
|
| Immunization, Secondary | 1 | 2024 | 114 | 0.210 |
Why?
|
| Stevens-Johnson Syndrome | 2 | 2017 | 15 | 0.200 |
Why?
|
| Neck | 1 | 2004 | 143 | 0.200 |
Why?
|
| Keratosis, Actinic | 1 | 2022 | 14 | 0.190 |
Why?
|
| Skin Abnormalities | 1 | 2022 | 35 | 0.190 |
Why?
|
| Piperazines | 3 | 2008 | 253 | 0.180 |
Why?
|
| Genital Neoplasms, Male | 1 | 2021 | 12 | 0.180 |
Why?
|
| Vulvar Neoplasms | 1 | 2021 | 22 | 0.180 |
Why?
|
| Dermatitis | 2 | 2019 | 28 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2017 | 786 | 0.170 |
Why?
|
| Keratoacanthoma | 2 | 2018 | 3 | 0.170 |
Why?
|
| Pyrimidines | 3 | 2008 | 419 | 0.160 |
Why?
|
| Panniculitis | 1 | 2019 | 19 | 0.160 |
Why?
|
| Radiodermatitis | 1 | 2019 | 8 | 0.160 |
Why?
|
| Lymphatic Metastasis | 4 | 2009 | 449 | 0.160 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2021 | 153 | 0.160 |
Why?
|
| Biopsy | 8 | 2019 | 1298 | 0.150 |
Why?
|
| Administration, Topical | 1 | 2019 | 142 | 0.150 |
Why?
|
| Esomeprazole | 1 | 2019 | 33 | 0.150 |
Why?
|
| Granuloma | 1 | 2019 | 66 | 0.150 |
Why?
|
| Anus Neoplasms | 1 | 2019 | 41 | 0.150 |
Why?
|
| Lymphoma, T-Cell | 1 | 2019 | 63 | 0.150 |
Why?
|
| Necrobiosis Lipoidica | 1 | 2018 | 1 | 0.150 |
Why?
|
| Granuloma Annulare | 1 | 2018 | 2 | 0.150 |
Why?
|
| Photosensitivity Disorders | 1 | 2018 | 11 | 0.150 |
Why?
|
| Neoplasms, Adnexal and Skin Appendage | 2 | 2008 | 5 | 0.140 |
Why?
|
| Antineoplastic Agents | 5 | 2008 | 1849 | 0.140 |
Why?
|
| Leptin | 2 | 2010 | 221 | 0.140 |
Why?
|
| Linear IgA Bullous Dermatosis | 1 | 2017 | 1 | 0.140 |
Why?
|
| Genome, Human | 2 | 2015 | 1336 | 0.140 |
Why?
|
| Transcription Factor 7-Like 1 Protein | 1 | 2017 | 8 | 0.140 |
Why?
|
| Follow-Up Studies | 5 | 2016 | 5416 | 0.130 |
Why?
|
| Sebaceous Gland Neoplasms | 2 | 2008 | 13 | 0.130 |
Why?
|
| Lipocalin-2 | 1 | 2017 | 32 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 607 | 0.130 |
Why?
|
| Parotid Neoplasms | 1 | 2016 | 16 | 0.130 |
Why?
|
| Receptors, Retinoic Acid | 2 | 2007 | 97 | 0.130 |
Why?
|
| Neoplasm Staging | 5 | 2019 | 1374 | 0.130 |
Why?
|
| Superinfection | 1 | 2016 | 7 | 0.130 |
Why?
|
| Enterobacter | 1 | 2016 | 15 | 0.130 |
Why?
|
| 12E7 Antigen | 2 | 2008 | 2 | 0.130 |
Why?
|
| Hair Follicle | 2 | 2007 | 35 | 0.130 |
Why?
|
| T-Lymphocytes | 1 | 2005 | 1770 | 0.120 |
Why?
|
| Hodgkin Disease | 1 | 2019 | 304 | 0.120 |
Why?
|
| Neoplasm, Residual | 1 | 2016 | 134 | 0.120 |
Why?
|
| Adenocarcinoma | 2 | 2017 | 1028 | 0.120 |
Why?
|
| Antigens, CD34 | 2 | 2008 | 109 | 0.120 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2016 | 59 | 0.120 |
Why?
|
| Administration, Cutaneous | 1 | 2015 | 68 | 0.120 |
Why?
|
| beta Catenin | 1 | 2017 | 228 | 0.120 |
Why?
|
| Eyelids | 1 | 2016 | 96 | 0.120 |
Why?
|
| Eye Infections, Bacterial | 1 | 2016 | 86 | 0.120 |
Why?
|
| Vancomycin | 1 | 2017 | 236 | 0.120 |
Why?
|
| Hydroa Vacciniforme | 1 | 2014 | 3 | 0.110 |
Why?
|
| Leishmania guyanensis | 1 | 2014 | 3 | 0.110 |
Why?
|
| Head and Neck Neoplasms | 2 | 2012 | 635 | 0.110 |
Why?
|
| Ki-67 Antigen | 1 | 2014 | 119 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 4 | 2007 | 254 | 0.110 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 814 | 0.110 |
Why?
|
| Carcinogenesis | 1 | 2017 | 362 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2012 | 2115 | 0.110 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2014 | 49 | 0.110 |
Why?
|
| Ultraviolet Rays | 1 | 2014 | 203 | 0.100 |
Why?
|
| Hidrocystoma | 1 | 2013 | 4 | 0.100 |
Why?
|
| Cell Proliferation | 3 | 2012 | 2558 | 0.100 |
Why?
|
| Cheek | 1 | 2013 | 25 | 0.100 |
Why?
|
| Nocardia | 1 | 2013 | 8 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 2 | 2017 | 2586 | 0.100 |
Why?
|
| Nocardia Infections | 1 | 2013 | 13 | 0.100 |
Why?
|
| Antigens, Neoplasm | 2 | 2008 | 403 | 0.100 |
Why?
|
| Facial Neoplasms | 1 | 2013 | 21 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 3 | 2009 | 1053 | 0.100 |
Why?
|
| Dapsone | 3 | 2021 | 6 | 0.100 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2013 | 23 | 0.100 |
Why?
|
| Kidney Transplantation | 1 | 2019 | 574 | 0.100 |
Why?
|
| Membrane Proteins | 3 | 2019 | 1605 | 0.100 |
Why?
|
| Snake Venoms | 1 | 2012 | 4 | 0.100 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2012 | 258 | 0.100 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2013 | 81 | 0.100 |
Why?
|
| Disease Progression | 5 | 2018 | 2245 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 2 | 2006 | 1583 | 0.090 |
Why?
|
| Biopsy, Needle | 2 | 2011 | 236 | 0.090 |
Why?
|
| Signal Transduction | 4 | 2010 | 4847 | 0.090 |
Why?
|
| Abscess | 1 | 2013 | 140 | 0.090 |
Why?
|
| Emigrants and Immigrants | 1 | 2014 | 157 | 0.090 |
Why?
|
| Epidermis | 1 | 2012 | 66 | 0.090 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2011 | 5 | 0.090 |
Why?
|
| Inflammation | 1 | 2019 | 1544 | 0.090 |
Why?
|
| Azathioprine | 1 | 2011 | 38 | 0.090 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2012 | 254 | 0.090 |
Why?
|
| Celiac Disease | 1 | 2011 | 73 | 0.080 |
Why?
|
| Mutation | 2 | 2015 | 6314 | 0.080 |
Why?
|
| Prednisone | 1 | 2011 | 253 | 0.080 |
Why?
|
| Gene Expression Profiling | 3 | 2019 | 1905 | 0.080 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 2 | 2006 | 102 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2010 | 205 | 0.080 |
Why?
|
| Neurothekeoma | 1 | 2009 | 2 | 0.080 |
Why?
|
| S100 Proteins | 1 | 2009 | 47 | 0.080 |
Why?
|
| Clusterin | 1 | 2009 | 11 | 0.080 |
Why?
|
| Lymph Nodes | 2 | 2008 | 397 | 0.080 |
Why?
|
| Epithelioid Cells | 1 | 2008 | 11 | 0.070 |
Why?
|
| Methotrexate | 1 | 2011 | 352 | 0.070 |
Why?
|
| Benzenesulfonates | 1 | 2008 | 12 | 0.070 |
Why?
|
| Neoplasm Metastasis | 5 | 2012 | 737 | 0.070 |
Why?
|
| Blotting, Western | 2 | 2010 | 1110 | 0.070 |
Why?
|
| Immunophenotyping | 2 | 2009 | 344 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2008 | 248 | 0.070 |
Why?
|
| Predictive Value of Tests | 4 | 2019 | 2298 | 0.070 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2011 | 293 | 0.070 |
Why?
|
| Quinolones | 1 | 2008 | 58 | 0.070 |
Why?
|
| Prognosis | 4 | 2011 | 5027 | 0.070 |
Why?
|
| Myosins | 1 | 2008 | 41 | 0.070 |
Why?
|
| Retrospective Studies | 7 | 2019 | 17415 | 0.070 |
Why?
|
| B-Lymphocytes | 1 | 2011 | 544 | 0.070 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 148 | 0.070 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2007 | 17 | 0.070 |
Why?
|
| Hutchinson's Melanotic Freckle | 1 | 2007 | 4 | 0.070 |
Why?
|
| Tumor Burden | 1 | 2008 | 258 | 0.070 |
Why?
|
| Neoplasms | 1 | 2022 | 2974 | 0.070 |
Why?
|
| Tissue Array Analysis | 4 | 2008 | 142 | 0.070 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2007 | 15 | 0.070 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2007 | 40 | 0.070 |
Why?
|
| Epidermal Cyst | 1 | 2007 | 18 | 0.070 |
Why?
|
| Adenoma, Sweat Gland | 1 | 2007 | 2 | 0.070 |
Why?
|
| DNA-Binding Proteins | 2 | 2007 | 2143 | 0.070 |
Why?
|
| Antibodies | 1 | 2008 | 372 | 0.070 |
Why?
|
| Genes, erbB-2 | 1 | 2007 | 38 | 0.070 |
Why?
|
| Sunlight | 1 | 2006 | 26 | 0.070 |
Why?
|
| Aminoquinolines | 1 | 2006 | 34 | 0.060 |
Why?
|
| Cadherins | 1 | 2008 | 182 | 0.060 |
Why?
|
| Adenoma | 1 | 2008 | 143 | 0.060 |
Why?
|
| Pyridines | 1 | 2008 | 249 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2011 | 674 | 0.060 |
Why?
|
| Transcription Factors | 3 | 2007 | 2718 | 0.060 |
Why?
|
| Galectin 3 | 1 | 2006 | 37 | 0.060 |
Why?
|
| Calcium-Binding Proteins | 1 | 2008 | 336 | 0.060 |
Why?
|
| Vasculitis | 1 | 2006 | 50 | 0.060 |
Why?
|
| Cell Nucleus | 2 | 2006 | 689 | 0.060 |
Why?
|
| Adenocarcinoma, Sebaceous | 1 | 2006 | 8 | 0.060 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2006 | 46 | 0.060 |
Why?
|
| Kidney Neoplasms | 2 | 2008 | 456 | 0.060 |
Why?
|
| Gene Amplification | 1 | 2007 | 241 | 0.060 |
Why?
|
| Cyclic AMP | 1 | 2006 | 240 | 0.060 |
Why?
|
| Diphtheria Toxin | 1 | 2005 | 14 | 0.060 |
Why?
|
| Microfilament Proteins | 1 | 2008 | 287 | 0.060 |
Why?
|
| Hypothyroidism | 1 | 2006 | 80 | 0.060 |
Why?
|
| Lymphoma, Follicular | 1 | 2005 | 30 | 0.060 |
Why?
|
| Carcinoma | 1 | 2008 | 303 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 510 | 0.060 |
Why?
|
| Skin Aging | 1 | 2005 | 12 | 0.060 |
Why?
|
| Alopecia | 1 | 2005 | 41 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2005 | 32 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2007 | 345 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2007 | 776 | 0.060 |
Why?
|
| Cell Cycle Proteins | 1 | 2009 | 698 | 0.060 |
Why?
|
| Interleukin-2 | 1 | 2005 | 243 | 0.060 |
Why?
|
| Lymphocytes | 1 | 2006 | 375 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2006 | 233 | 0.060 |
Why?
|
| Thyrotropin-Releasing Hormone | 1 | 2004 | 10 | 0.060 |
Why?
|
| Oncogene Proteins | 1 | 2005 | 157 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2006 | 392 | 0.060 |
Why?
|
| Precancerous Conditions | 1 | 2007 | 280 | 0.050 |
Why?
|
| Young Adult | 2 | 2016 | 9966 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2007 | 500 | 0.050 |
Why?
|
| Eosinophils | 1 | 2005 | 122 | 0.050 |
Why?
|
| Omalizumab | 1 | 2024 | 35 | 0.050 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2003 | 11 | 0.050 |
Why?
|
| Imatinib Mesylate | 3 | 2008 | 48 | 0.050 |
Why?
|
| Treatment Outcome | 5 | 2019 | 12963 | 0.050 |
Why?
|
| Cell Survival | 1 | 2006 | 882 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2007 | 831 | 0.050 |
Why?
|
| Benzamides | 3 | 2008 | 123 | 0.050 |
Why?
|
| SOXE Transcription Factors | 1 | 2022 | 15 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 1059 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2005 | 814 | 0.050 |
Why?
|
| Nose | 1 | 2022 | 105 | 0.050 |
Why?
|
| Pregnancy | 1 | 2014 | 7588 | 0.050 |
Why?
|
| Leg | 1 | 2022 | 140 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2009 | 2025 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2004 | 589 | 0.040 |
Why?
|
| Retinoids | 1 | 2021 | 29 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 1158 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2011 | 1413 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2006 | 3120 | 0.040 |
Why?
|
| Graft vs Host Disease | 1 | 2006 | 621 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 2745 | 0.040 |
Why?
|
| Heme Oxygenase-1 | 1 | 2019 | 29 | 0.040 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2019 | 21 | 0.040 |
Why?
|
| Debridement | 1 | 2019 | 93 | 0.040 |
Why?
|
| Necrosis | 1 | 2019 | 211 | 0.040 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2019 | 127 | 0.040 |
Why?
|
| Epithelial Cells | 2 | 2018 | 923 | 0.040 |
Why?
|
| Elastic Tissue | 1 | 2018 | 20 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2004 | 1071 | 0.040 |
Why?
|
| Elastin | 1 | 2018 | 32 | 0.040 |
Why?
|
| Models, Anatomic | 1 | 2019 | 104 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2019 | 146 | 0.040 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2019 | 118 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2012 | 962 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 4717 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2006 | 1191 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 312 | 0.030 |
Why?
|
| Heterografts | 1 | 2017 | 200 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2019 | 3676 | 0.030 |
Why?
|
| DNA Primers | 2 | 2008 | 652 | 0.030 |
Why?
|
| Wound Healing | 1 | 2019 | 486 | 0.030 |
Why?
|
| Cytoplasm | 2 | 2006 | 300 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 1316 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2017 | 274 | 0.030 |
Why?
|
| Cuba | 1 | 2014 | 7 | 0.030 |
Why?
|
| Panama | 1 | 2014 | 14 | 0.030 |
Why?
|
| Antiprotozoal Agents | 1 | 2014 | 42 | 0.030 |
Why?
|
| Amphotericin B | 1 | 2014 | 91 | 0.030 |
Why?
|
| Adolescent | 5 | 2010 | 20557 | 0.030 |
Why?
|
| Travel | 1 | 2014 | 125 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2014 | 248 | 0.020 |
Why?
|
| Child | 5 | 2014 | 25830 | 0.020 |
Why?
|
| Hand | 1 | 2013 | 107 | 0.020 |
Why?
|
| Hyperpigmentation | 1 | 2011 | 13 | 0.020 |
Why?
|
| Teaching Rounds | 1 | 2011 | 33 | 0.020 |
Why?
|
| Mice | 2 | 2019 | 18897 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 4827 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2010 | 3781 | 0.020 |
Why?
|
| S100 Calcium Binding Protein A6 | 1 | 2009 | 5 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 1301 | 0.020 |
Why?
|
| Animals | 3 | 2019 | 35898 | 0.020 |
Why?
|
| Lymphomatoid Papulosis | 1 | 2009 | 3 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 429 | 0.020 |
Why?
|
| Glioblastoma | 1 | 2013 | 373 | 0.020 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2009 | 15 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2011 | 207 | 0.020 |
Why?
|
| Time Factors | 1 | 2019 | 6483 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 62 | 0.020 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2009 | 47 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 1704 | 0.020 |
Why?
|
| Back | 1 | 2008 | 11 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2010 | 299 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2012 | 1652 | 0.020 |
Why?
|
| Niacinamide | 1 | 2008 | 31 | 0.020 |
Why?
|
| DNA Mismatch Repair | 1 | 2008 | 54 | 0.020 |
Why?
|
| Thorax | 1 | 2008 | 71 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 2008 | 56 | 0.020 |
Why?
|
| Extremities | 1 | 2008 | 87 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2008 | 102 | 0.020 |
Why?
|
| Melanins | 1 | 2007 | 19 | 0.020 |
Why?
|
| Abdomen | 1 | 2008 | 136 | 0.020 |
Why?
|
| Keratin-20 | 1 | 2007 | 12 | 0.020 |
Why?
|
| Merkel Cells | 1 | 2007 | 5 | 0.020 |
Why?
|
| Hair Diseases | 1 | 2007 | 12 | 0.020 |
Why?
|
| Ankle | 1 | 2007 | 30 | 0.020 |
Why?
|
| Synaptophysin | 1 | 2007 | 20 | 0.020 |
Why?
|
| Chromogranins | 1 | 2007 | 28 | 0.020 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2007 | 31 | 0.020 |
Why?
|
| Axilla | 1 | 2007 | 44 | 0.020 |
Why?
|
| Thoracic Wall | 1 | 2007 | 40 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2007 | 169 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 312 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2006 | 12 | 0.020 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2006 | 19 | 0.020 |
Why?
|
| Trastuzumab | 1 | 2007 | 154 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2006 | 65 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 1124 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2007 | 176 | 0.020 |
Why?
|
| Claudin-1 | 1 | 2005 | 20 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 641 | 0.010 |
Why?
|
| Procollagen | 1 | 2005 | 17 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2006 | 136 | 0.010 |
Why?
|
| Blood Vessels | 1 | 2005 | 104 | 0.010 |
Why?
|
| Protein Array Analysis | 1 | 2005 | 105 | 0.010 |
Why?
|
| Phototherapy | 1 | 2005 | 39 | 0.010 |
Why?
|
| Low-Level Light Therapy | 1 | 2005 | 19 | 0.010 |
Why?
|
| United States | 2 | 2014 | 11649 | 0.010 |
Why?
|
| Nuclear Receptor Coactivators | 1 | 2005 | 76 | 0.010 |
Why?
|
| Risk Factors | 1 | 2019 | 10883 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2005 | 378 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2005 | 477 | 0.010 |
Why?
|
| COP9 Signalosome Complex | 1 | 2004 | 13 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 1169 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2005 | 432 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2004 | 61 | 0.010 |
Why?
|
| Heat-Shock Proteins | 1 | 2005 | 204 | 0.010 |
Why?
|
| Base Sequence | 1 | 2008 | 3146 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 1448 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2013 | 1408 | 0.010 |
Why?
|
| Peptide Hydrolases | 1 | 2004 | 149 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 587 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 3086 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2005 | 798 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2005 | 499 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2007 | 558 | 0.010 |
Why?
|
| Disease Management | 1 | 2006 | 566 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2006 | 1237 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2006 | 1341 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 2865 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 1306 | 0.010 |
Why?
|
| Texas | 1 | 2005 | 3656 | 0.010 |
Why?
|
| Biomarkers | 1 | 2005 | 3405 | 0.010 |
Why?
|
| Phenotype | 1 | 2005 | 4570 | 0.010 |
Why?
|
| Infant | 1 | 2007 | 13142 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2007 | 14842 | 0.010 |
Why?
|